US Stock Market Movement: Zenas BioPharma Surges on October 19th Driven by Abeximab Phase III Data

Zenas BioPharma October 19 Surge Analysis

Keywords: Obexelimab Phase III Data

On October 12, the company announced new data from the phase III INDIGO study of Obexelimab for the treatment of IgG4-related disease: the open-label extension showed sustained clinical activity; analysis of the randomized controlled phase indicated that significantly fewer patients experienced clinically meaningful cumulative glucocorticoid toxicity by week 52; preliminary results from the vaccine sub-study showed that patients still exhibited a vaccine response after the treatment discontinuation observation period.

(Disclaimer: This content is compiled by AI technology based on publicly available information for reference only and does not constitute investment advice.)